Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on MDMA Bioavailability
NCT05147402Phase 1Completed
- Sponsor
- Lykos Therapeutics
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of midomafetamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Lykos Therapeutics. Primary endpoints: Area under the curve from dosing time to last measurement - Plasma concentration of MDMA and Area under the curve from dosing time to last measurement - Plasma concentration of active metabolite MDA. Started Jul 2022; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05147402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147402.